Lexaria Bioscience (LEXX) Depreciation and Depletion (2010 - 2022)

Lexaria Bioscience has disclosed Depreciation and Depletion across 13 years of filings, most recently posting $23893.0 for Q2 2022.

• Depreciation and Depletion for Q2 2022 came in at $23893.0, down 14.45% year-over-year; the trailing twelve-month figure through May 2022 was $105916.0 (down 5.99% YoY), and the FY2021 annual result was $111718.0, down 0.92% from the prior year.
• Depreciation and Depletion came in at $23893.0 for Q2 2022 at Lexaria Bioscience, down from $26163.0 in the prior quarter.
• In the past five years, Depreciation and Depletion ranged from a high of $28875.0 in Q3 2020 to a low of $462.0 in Q1 2018.
• The 5-year median for Depreciation and Depletion is $26853.5 (2019), against an average of $20274.2.
• Across the five-year window, Depreciation and Depletion surged 4200.95% in 2019 and retreated 14.45% in 2022, its largest moves.
• Lexaria Bioscience's Depreciation and Depletion stood at $1603.0 in 2018, then jumped by 1616.28% to $27512.0 in 2019, then grew by 1.52% to $27929.0 in 2020, then climbed by 0.0% to $27930.0 in 2021, then declined by 14.45% to $23893.0 in 2022.
• The last three Depreciation and Depletion figures came in at $23893.0 (Q2 2022), $26163.0 (Q1 2022), and $27930.0 (Q4 2021), per Business Quant data.